Aldeyra Therapeutics to Participate in Upcoming Virtual Investor Conferences
03 March 2021 - 12:00AM
Business Wire
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today
announced that President and Chief Executive Officer Todd C. Brady,
M.D., Ph.D. will participate in analyst-led fireside conversations
at the H.C. Wainwright Global Life Sciences Conference and the
Oppenheimer 31st Annual Healthcare Conference.
- H.C. Wainwright Global Life Sciences Conference Date:
Tuesday, March 9, 2021 Time: 7:00 a.m. ET
- Oppenheimer 31st Annual Healthcare Conference Date:
Tuesday, March 16, 2021 Time: 9:20 a.m. ET
To view these events, please visit the Investor & Media page
of the company’s website. After the presentations, the events will
remain archived on the website for 90 days.
About Aldeyra Therapeutics, Inc.
Aldeyra Therapeutics is a clinical-stage biotechnology company
focused on the development of novel therapies with the potential to
improve the lives of patients with immune-mediated diseases. Two of
the company’s lead investigational compounds, reproxalap and
ADX-629, target RASP (reactive aldehyde species), which are
elevated in ocular and systemic inflammatory disease and result in
cytokine release via activation of a broad array of inflammatory
factors, including NF-κB, inflammasomes, and Scavenger Receptor A.
Reproxalap is being evaluated in Phase 3 clinical trials in
patients with dry eye disease and allergic conjunctivitis. The
company’s clinical pipeline also includes ADX-2191, a dihydrofolate
reductase inhibitor in Phase 3 testing for proliferative
vitreoretinopathy, and ADX-1612, a chaperome inhibitor in
development for COVID-19 and ovarian cancer. For more information,
visit https://www.aldeyra.com/ and follow us on LinkedIn, Facebook,
and Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210302005108/en/
Corporate Contact: Joshua Reed Aldeyra Therapeutics, Inc.
Tel: 781-761-4904 ext. 218 jreed@aldeyra.com
Investor & Media Contact: Scott Solomon Sharon
Merrill Associates, Inc. Tel: 617-542-5300
ALDX@investorrelations.com
Aldeyra Therapeutics (NASDAQ:ALDX)
Historical Stock Chart
From Apr 2024 to May 2024
Aldeyra Therapeutics (NASDAQ:ALDX)
Historical Stock Chart
From May 2023 to May 2024